|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-2 (GLP-2) is effective for treating SBS, but is rapidly inactivated by dipeptidyl peptidase IV (DPP4).
|
31576468 |
2020 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A newer treatment for SBS is GLP-2 analogue.
|
31606228 |
2019 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Animals were divided into three groups: SBR and total parenteral nutrition (TPN) (SBS/TPN group), SBR and TPN plus GLP-2 at 1 µg/kg/h [SBS/TPN/GLP-2 (low) group], and SBR and TPN plus GLP-2 at 10 µg/kg/h [SBS/TPN/GLP-2 (high) group].
|
31555865 |
2019 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome (SBS), there is emerging evidence that GLP-2 may play a role in the restoration of the disturbed homeostatic feedback in the gut-liver axis and may ameliorate SBS-associated liver damage.
|
31326433 |
2019 |
|
Brooke-Spiegler syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the international variation in the pathophysiology of SBS-IF varies significantly, which can have a bearing on PN requirements and outcomes when GLP-2 analogues are used.
|
30111847 |
2019 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
MAT was negatively correlated with lumbar spine BMD in normal individuals, but not in those in the SBS group, who otherwise showed a positive correlation between MAT and GLP1.
|
29509291 |
2018 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviews the physiology of GLP-2 with an emphasis on the known or potential roles in infants and children with SBS and IF.
|
30342598 |
2018 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to these effects GLP-2 is used in the treatment of short bowel syndrome (SBS).
|
29231791 |
2018 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-2 analog is now the treatment of reference in SBS patients with chronic intestinal failure.
|
29702489 |
2018 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Teduglutide is an analog of glucagon-like peptide 2 (GLP-2) which is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support.
|
29848084 |
2018 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current research shows that over and above known trophic effects, the combination of GLP-2 and EGF synergistically lengthens the bowel in neonatal piglet models of SBS.
|
28104586 |
2017 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed.
|
29202475 |
2017 |
|
Brooke-Spiegler syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After fecal transfer, we also show that gnotobiotic rats exhibited high levels of circulating GLP-1 and ghrelin, two hormones that are known to be induced in SBS patients.
|
28469580 |
2017 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sprague Dawley rats were randomized to four treatments: Transected Bowel (TB) (n = 8), TB + GLP-2 (2.5 nmol/kg/h, n = 8), SBS (n = 5), or SBS + GLP-2 (2.5 nmol/kg/h, n = 9).
|
28738080 |
2017 |
|
Brooke-Spiegler syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Teduglutide is a GLP-2 analogue indicated for treatment of adults with short bowel syndrome (SBS).
|
27433811 |
2017 |